T regulatory cells and the control of allergic disease

Expert Opinion on Biological Therapy

Volumn 6, Issue 2, 2006, Pages 121-133

  Xystrakis, E ^b   Boswell, S E ^b   Hawrylowicz, C M ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b NONE

Author keywords

Allergy; Asthma; Human; IL 10; Immunotherapy; Peripheral tolerance; T regulatory cells

Indexed keywords

ALLERGEN; INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA;

ALLERGIC DISEASE; ASTHMA; CELL MANIPULATION; DESENSITIZATION; DISEASE CONTROL; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; TH2 CELL;

ALLERGENS; ANIMALS; ASTHMA; HUMANS; HYPERSENSITIVITY; HYPERSENSITIVITY, IMMEDIATE; IMMUNOTHERAPY; INFLAMMATION; INTERLEUKIN-10; MODELS, BIOLOGICAL; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; TH2 CELLS; TRANSFORMING GROWTH FACTOR BETA;

EID: 32944481883     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.6.2.121     Document Type: Review

References (131)

1. ROBINSON DS, HAMID Q, YING S et al.: Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N. Engl. J. Med. (1992) 326:298-304. An important early study that demonstrated the presence of mRNA for Th2 cytokines in T cells in the lungs of patients with allergic asthma.
2. ROMAGNANI S: Regulation of the development of type 2 T-helper cells in allergy. Curr. Opin. Immunol. (1994) 6:838-846.
3. GAVETT SH, O'HEARN DJ, LI X et al.: Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice. J. Exf. Med. (1995) 182:1527-1536.
4. HOFSTRA CL, VAN ARK I, HOFMAN G et al.: Prevention of Th2-like cell responses by coadministration of IL-12 and IL-18 is associated with inhibition of antigen-induced airway hyperresponsiveness, eosinophilia, and serum IgE levels. J. Immunol. (1998) 161:5054-5060.
5. COHN L, HERRICK C, NIU N, HOMER R, BOTTOMLY K: IL-4 promotes airway eosinophilia by suppressing IFN-gamma production: defining a novel role for IFN-gamma in the regulation of allergic airway inflammation. J. Immunol. (2001) 166:2760-2767.
6. UMETSU DT, MCINTIRE JJ, AKBARI O, MACAUBAS C, DEKRUYFF RH: Asthma: an epidemic of deregulated immunity. Nat. Immunol. (2002) 3:715-720.
7. RANDOLPH DA, CARRUTHERS CJ, SZABO SJ, MURPHY KM, CHAPLIN DD: Modulation of airway inflammation by passive transfer of allergen-specific Th1 and Th2 cells in a mouse model of asthma. J. Immunol. (1999) 162:2375-2383.
8. RANDOLPH DA, STEPHENS R, CARRUTHERS CJ, CHAPLIN DD: Cooperation between Th1 and Th2 cells in a murine model of eosinophilic airway inflammation. J. Clin. Invest. (1999) 104:1021-1029.
9. MARSHALL JD, ABTAHI S, EIDEN JJ et al.: Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy. J. Allergy Clin. Immunol. (2001) 108:191-197.
10. SIMONS FE, SHIKISHIMA Y, VAN NEST G, EIDEN JJ, HAYGLASS KT: Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J. Allergy Clin. Immunol. (2004) 113:1144-1151.
11. ROMAGNANI S: Immunologic influences on allergy and the TH1/TH2 balance. J. Allergy Clin. Immunol. (2004) 113:395-400.
12. COOKSON W, MOFFATT M: Making sense of asthma genes. N. Engl. J. Med. (2004) 351:1794-1796.
13. WILLS-KARP M, SANTELIZ, KARP CL: The germless theory of allergic disease: revisiting the hygiene hypothesis. Nat. Rev. Immunol (2001) 1:69-75.
14. + Tregs may be impaired in subjects with active allergic disease.
15. GERSHON RK, KONDO K: Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology (1970) 18:723-737.
16. SAKAGUCHI S: Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. (2004) 22:531-562. See [17].
17. + Tregs.
18. FONTENOT JD, RUDENSKY AY: A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat. Immunol. (2005) 6:331-337.
19. JORDAN MS, BOESTEANU A, REED AJ et al.: Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat. Immunol. (2001) 2:301-306.
20. BAECHER-ALLAN C, BROWN JA, FREEMAN GJ, HAFLER DA: CD4+CD25 high regulatory cells in human peripheral blood. J. Immunol. (2001) 167:1245-1253.
21. READ S, MALMSTROM V, POWRIE F: Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J. Exf. Med. (2000) 192:295-302.
22. TAKAHASHI T, TAGAMI T, YAMAZAKI S et al.: Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exf. Med. (2000) 192:303-310.
23. SHIMIZU J, YAMAZAKI S, TAKAHASHI T, ISHIDA Y, SAKAGUCHI S: Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol. (2002) 3:135-142.
24. HORI S, NOMURA T, SAKAGUCHI S: Control of regulatory T cell development by the transcription factor Foxp3. Science (2003) 299:1057-1061.
25. KHATTRI R, COX T, YASAYKO SA, RAMSDELL F: An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat. Immunol. (2003) 4:337-342.
26. FONTENOT JD, GAVIN MA, RUDENSKY AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. (2003) 4:330-336.
27. FONTENOT JD, RASMUSSEN JP, WILLIAMS LM et al.: Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity (2005) 22:329-341.
28. WALKER MR, KASPROWICZ DJ, GERSUK VH et al.: Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J. Clin. Invest. (2003) 112:1437-1443.
29. CHEN W, JIN W, HARDEGEN N et al.: Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. (2003) 198:1875-1886.
30. O'GARRA A, VIEIRA P: Regulatory T cells and mechanisms of immune system control. Nat. Med. (2004) 10:801-805. See [31].
31. HAWRYLOWICZ CM, O'GARRA A: Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. Nat. Rev. Immunol. (2005) 5:271-283. Key reviews describing the induction and biology of inducible Treg populations.
32. PAUST S, LU L, MCCARTY N, CANTOR H: Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. Proc. Natl. Acad. Sci. USA (2004) 101:10398-10403.
33. TANG Q, BODEN EK, HENRIKSEN KJ et al.: Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. Eur. J. Immunol. (2004) 34:2996-3005.
34. GROSSMAN WJ, VERBSKY JW, BARCHET W et al.: Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity (2004) 21:589-601.
35. STASSEN M, JONULEIT H, MULLER C et al.: Differential regulatory capacity of CD25+ T regulatory cells and preactivated CD25+ T regulatory cells on development, functional activation, and proliferation of Th2 cells. J. Immunol. (2004) 173:267-274.
36. XU D, LIU H, M KOMAI-KOMA et al.: CD4+CD25+ regulatory T cells suppress differentiation and functions of Th1 and Th2 cells, Leishmania major infection, and colitis in mice. J. Immunol. (2003) 170:394-399.
37. PELLETIER L, SAVIGNAC M, XYSTRAKIS E et al.: Self major histocompatibility complex class-II-specific regulatory CD4 T cells prevent both Th1-and Th2-mediated autoimmune diseases in the rat. Microbes Infect. (2001) 3:955-960.
38. CUROTTO DE LAFAILLE MA, MURIGLAN S, SUNSHINE MJ et al.: Hyper immunoglobuiin E response in mice with monoclonal populations of B and T lymphocytes. J. Exp. Med. (2001) 194:1349-1359.
39. HADEIBA H, LOCKSLEY RM: Lung CD25 CD4 regulatory T cells suppress type 2 immune responses but not bronchial hyperreactivity. J. Immunol. (2003) 170:5502-5510.
40. + Tregs may actively prevent allergen-specific Th2 cytokine responses in non-atopic individuals.
41. + Tregs may actively prevent allergen-specific Th2 cytokine responses in non-atopic individuals.
42. + Tregs may be impaired in subjects with active allergic disease.
43. GRINDEBACKE H, WING K, ANDERSSON AC et al.: Defective suppression of Th2 cytokines by CD4CD25 regulatory T cells in birch allergics during birch pollen season. Clin. Exp. Allergy (2004) 34:1364-1372.
44. VUKMANOVIC-STEJIC M, MCQUAID A, BIRCH KE et al.: Relative impact of CD4+CD25+ regulatory T cells and tacrolimus on inhibition of T-cell proliferation in patients with atopic dermatitis. Br. J. Dermatol. (2005) 153:750-757.
45. + Tregs than Th1 cells, with potentially important implications for allergic disease.
46. BAECHER-ALLAN C, VIGLIETTA V, HAFLER DA: Inhibition of human CD4(+)CD25(+high) regulatory T cell function. J. Immunol. (2002) 169:6210-6217.
47. + Tregs.
48. TANG Q, HENRIKSEN KJ, BI M et al.: In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J. Exp. Med. (2004) 199:1455-1465.
49. WALKER LS, CHODOS A, EGGENA M, DOOMS H, ABBAS AK: Antigen-dependent proliferation of CD4+ CD25+ regulatory T cells in vivo. J. Exp. Med. (2003) 198:249-258.
50. LEVINGS MK, SANGREGORIO R, RONCAROLO MG: Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J. Exp. Med. (2001) 193:1295-1302.
51. HOFFMANN P, EDER R, LA KUNZ-SCHUGHART ANDREESEN R, EDINGER M: Large-scale in vitro expansion of polyclonal human CD4(+)CD25 high regulatory T cells. Blood (2004) 104:895-903.
52. GODFREY WR, GE YG, SPODEN DJ et al.: In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. Blood (2004) 104:453-461.
53. WOO EY, YEH H, CHU CS et al.: Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. (2002) 168:4272-4276.
54. CAO D, MALMSTROM V, BAECHER-ALLAN C et al.: Isolation and functional characterization of regulatory CD25brightCD4+ T cells from the target organ of patients with rheumatoid arthritis. Eur. J. Immunol. (2003) 33:215-223.
55. RUPRECHT CR, GATTORNO M, FERLITO F et al.: Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia. J. Exp. Med. (2005) 201:1793-1803. See [56].
56. + Tregs is impaired by inflammatory signals in tissues that represent the active site of disease.
57. POWRIE F, READ S, MOTTET C, UHLIG H, MALOY K: Control of immune pathology by regulatory T cells. Novartis Found. Symp. (2003) 252:92-98; discussion 98-105, 106-114.
58. BLUESTONE JA, ABBAS AK: Natural versus adaptive regulatory T cells. Nat. Rev. Immunol. (2003) 3:253-257.
59. BACCHETTA R, BIGLER M, TOURAINE JL et al.: High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J. Exp. Med. (1994) 179:493-502.
60. WEINER HL: Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells. Microbes Infect. (2001)3:947-954.
61. MOORE KW, DE WAAL MALEFYT R, COFFMAN RL, O'GARRA A: Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. (2001) 19:683-765.
62. ASADULLAH K, STERRY W, VOLK HD: Interleukin-10 therapy-review of a new approach. Pharmacol. Rev. (2003) 55:241-269.
63. GORELIK L, FLAVELL RA: Transforming growth factor-beta in T-cell biology. Nat. Rev. Immunol. (2002) 2:46-53.
64. SCHMIDT-WEBER CB, KUNZMANN S, BLASER K: TGF-beta-mediated control of allergen-specific T-cell responses. Curr. Allergy Asthma Rep. (2002) 2:259-262.
65. COTTREZ F, HURST SD, COFFMAN RL, GROUX H: T regulatory cells 1 inhibit a Th2-specific response in vivo. J. Immunol. (2000) 165:4848-4853.
66. OH JW, SEROOGY CM, MEYER EH et al.: CD4 T-helper cells engineered to produce IL-10 prevent allergen-induced airway hyperreactivity and inflammation. J. Allergy Clin. Immunol. (2002) 110:460-468.
67. STAMPFLI MR, CWIARTKA M, GAJEWSKA BU et al.: Interleukin-10 gene transfer to the airway regulates allergic mucosal sensitization in mice. Am. J. Respir. Cell Mol. Biol. (1999) 21:586-596.
68. NAKAGOME K, DOHI M, OKUNISHI K et al.: In vivo IL-10 gene delivery suppresses airway eosinophilia and hyperreactivity by down-regulating APC functions and migration without impairing the antigen-specific systemic immune response in a mouse model of allergic airway inflammation. J. Immunol. (2005) 174:6955-6966.
69. BORISH L, AARONS A, RUMBYRT J et al.: Interleukin-10 regulation in normal subjects and patients with asthma. J. Allergy Clin. Immunol. (1996) 97:1288-1296. See [71].
70. LIM S, CRAWLEY E, WOO P, BARNES PJ: Haplotype associated with low interleukin-10 production in patients with severe asthma. Lancet (1998) 352:113. See [71].
71. HEATON T, ROWE J, TURNER S et al.: An immunoepidemiological approach to asthma: identification of in-vitro T-cell response patterns associated with different wheezing phenotypes in children. Lancet (2005) 365:142-149. Studies showing that the presence of the anti-inflammatory cytokine IL-10 is inversely correlated with disease severity.
72. AKDIS M, VERHAGEN J, TAYLOR A et al.: Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J. Exp. Med. (2004) 199:1567-1575. A recent study demonstrating that IL-10-secreting T cells are the dominant subset specific for common environmental allergens in healthy individuals, whereas there is an increased frequency of IL-4-secreting allergen-specific T cells in allergic patients.
73. BELLINGHAUSEN I, METZ G, ENK AH et al.: Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur. J. Immunol. (1997) 27:1131-1139. See [74].
74. AKDIS CA, BLESKEN T, AKDIS M, WUTHRICH B, BLASER K: Role of interleukin 10 in specific immunotherapy. J. Clin. Invest. (1998) 102:98-106. Early studies demonstrating the correlation between tolerance to allergen and IL-10 production in beekeepers who become naturally tolerant to allergen (following multiple stings), and the induction of IL-10 synthesis in response to allergen following successful allergen immunotherapy.
75. JOHN M, LIM S, SEYBOLD J et al.: Inhaled corticosteroids increase interleukin-10 but reduce macrophage inflammatory protein-1a, granulocyte-macrophage stimulating factor and Interferon-g release from alveolar macrophages in asthma. Am. J. Respir. Crit. Care Med. (1998) 157:256-262. See [77].
76. RICHARDS DF, FERNANDEZ M, CAULFIELD J, HAWRYLOWICZ CM: Glucocorticoids drive human CD8(+) T cell differentiation towards a phenotype with high IL-10 and reduced IL-4, IL-5 and IL-13 production. Eur.J. Immunol. (2000) 30:2344-2354. See [77].
77. HAWRYLOWICZ C, RICHARDS D, LOKE TK, CORRIGAN C, LEE T: A defect in corticosteroid-induced IL-10 production in T lymphocytes from corticosteroid-resistant asthmatic patients. J. Allergy Clin. Immunol. (2002) 109:369-370. Evidence that glucocorticoids induce the production of IL-10 in vivo and in vitro, and that this is impaired in individuals who show a poor clinical response following glucocorticoid treatment, suggesting a role for IL-10 in the clinical efficacy of steroid action.
78. SMITH TR, ALEXANDER C, KAY AB, LARCHE M, ROBINSON DS: Cat allergen peptide immunotherapy reduces CD4 T cell responses to cat allergen but does not alter suppression by CD4 CD25 T cells: a double-blind placebo-controlled study. Allergy (2004) 59:1097-1101.
79. DAO NGUYEN X, ROBINSON DS: Fluticasone propionate increases CD4CD25 T regulatory cell suppression of allergen-stimulated CD4CD25 T cells by an IL-10-dependent mechanism. J. Allergy Clin. Immunol. (2004) 114:296-301.
80. HANSEN G, MCINTIRE JJ, YEUNG VP et al.: CD4(+) T helper cells engineered to produce latent TGF-beta1 reverse allergen-induced airway hyperreactivity and inflammation. J. Clin. Invest. (2000) 105:61-70.
81. KUNZMANN S, MANTEL PY, WOHLFAHRT JG et al.: Histamine enhances TGF-beta1-mediated suppression of Th2 responses. FASEB J. (2003) 17:1089-1095.
82. MCMILLAN SJ, LLOYD CM: Prolonged allergen challenge in mice leads to persistent airway remodelling. Clin. Exp. Allergy (2004) 34:497-507.
83. MCMILLAN SJ, XANTHOU G, LLOYD CM: Manipulation of allergen-induced airway remodeling by treatment with anti-TGF-beta antibody: effect on the Smad signaling pathway. J. Immunol. (2005) 174:5774-5780.
84. APOSTOLOU I, VON BOEHMER H: In vivo instruction of suppressor commitment in naive T cells. J. Exp. Med. (2004) 199:1401-1408.
85. SUNDSTEDT A, O'NEILL EJ, NICOLSON KS, WRAITH DC: Role for IL-10 in suppression mediated by peptide-induced regulatory T cells in vivo. J. Immunol. (2003) 170:1240-1248.
86. GROUX H, O'GARRA A, BIGLER M et al.: Generation of a novel regulatory CD4+ T-cell population, which inhibits antigen-specific T-cell responses. Nature (1997) 389:737-742.
87. JONULEIT H, SCHMITT E, SCHULER G, KNOP J, ENK AH: Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J. Exp. Med. (2000) 192:1213-1222.
88. MAHNKE K, QIAN Y, KNOP J, ENK AH: Induction of CD4+/CD25+ regulatory T cells by targeting of antigens to immature dendritic cells. Blood (2003) 101:4862-4869.
89. LEVINGS MK, SANGREGORIO R, GALBIATI F et al.: IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells. J. Immunol. (2001) 166:5530-5539.
90. ELMETS CA, BERGSTRESSER PR, TIGELAAR RE, WOOD PJ, STREILEIN JW: Analysis of the mechanism of unresponsiveness produced by haptens painted on skin exposed to low dose ultraviolet radiation. J. Exp. Med. (1983) 158:781-794.
91. BARRAT FJ, CUA DJ, BOONSTRA A et al.: In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J. Exp. Med. (2002) 195:603-616.
92. VIEIRA PL, CHRISTENSEN JR, MINAEE S et al.: IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4+CD25+ regulatory T cells. J. Immunol. (2004) 172:5986-5993.
93. PEEK EJ, RICHARDS DF, FAITH A et al.: Interleukin 10 secreting 'regulatory' T cells induced by glucocorticoids and beta2-agonists. Am. J. Respir. Cell Mol. Biol. (2005) 33:105-111.
94. HACKSTEIN H, THOMSON AW: Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat. Rev. Immunol. (2004) 4:24-34.
95. ROBINSON DS, LARCHE M, DURHAM SR: Tregs and allergic disease. J. Clin. Invest. (2004) 114:1389-1397.
96. HOYNE GF, O'HEHIR RE, WRAITH DC, THOMAS WR, LAMB JR: Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice. J. Exp. Med. (1993) 178:1783-1788.
97. VAN HALTEREN AG, VAN DER CAMMEN MJ, COOPER D et al.: Regulation of antigen-specific IgE, IgG1, and mast cell responses to ingested allergen by mucosal tolerance induction. J. Immunol. (1997) 159:3009-3015.
98. AKBARI O, DEKRUYFF RH, UMETSU DT: Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat. Immunol. (2001) 2:725-731.
99. RUSSO M, NAHORI MA, LEFORT J et al.: Suppression of asthma-like responses in different mouse strains by oral tolerance. Am. J. Respir. Cell Mol. Biol. (2001) 24:518-526.
100. AKBARI O, FREEMAN GJ, MEYER EH et al.: Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat. Med. (2002) 8:1024-1032.
101. ZUANY-AMORIM C, SAWICKA E, MANLIUS C et al.: Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells. Nat. Med. (2002) 8:625-629.
102. OSTROUKHOVA M, SEGUIN-DEVAUX C, ORISS TB et al.: Tolerance induced by inhaled antigen involves CD4(+) T cells expressing membrane-bound TGF-beta and FOXP3. J. Clin. Invest. (2004) 114:28-38.
103. AKDIS CA, AKDIS M, BLESKEN T et al.: Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J. Clin. Invest. (1996) 98:1676-1683.
104. VAN NEERVEN RJ, WIKBORG T, LUND G et al.: Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J. Immunol. (1999) 163:2944-2952.
105. JEANNIN P, LECOANET S, DELNESTE Y, GAUCHAT JF, BONNEFOY JY: IgE versus IgG4 production can be differentially regulated by IL-10. J. Immunol. (1998) 160:3555-3561.
106. TILL SJ, FRANCIS JN, NOURI-ARIA K, DURHAM SR: Mechanisms of immunotherapy. J. Allergy Clin. Immunol. (2004) 113:1025-1034; quiz 1035. A recent comprehensive review of the immunological mechanisms associated with allergen immunotherapy.
107. JUTEL M, AKDIS M, BUDAK F et al.: IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur. J. Immunol. (2003) 33:1205-1214.
108. KUEHR J, BRAUBURGER J, ZIELEN S et al.: Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J. Allergy Clin. Immunol. (2002) 109:274-280.
109. ROLINCK-WERNINGHAUS C, HAMELMANN E, KEIL T et al.: The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy (2004) 59:973-979.
110. NOVAK N, BIEBER T, KATOH N: Engagement of Fc epsilon RI on human monocytes induces the production of IL-10 and prevents their differentiation in dendritic cells. J. Immunol. (2001) 167:797-804.
111. MULLER U, AKDIS CA, FRICKER M et al.: Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J. Allergy Clin. Immunol. (1998) 101:747-754.
112. OLDFIELD WL, LARCHE M, KAY AB: Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet (2002) 360:47-53.
113. LARCHE M, WRAITH DC: Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat. Med. (2005) 11:S69-S76.
114. VERHOEF A, ALEXANDER C, KAY AB, LARCHE M: T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity. PLoS Med. (2005)2:e78.
115. DUREZ P, ABRAMOWICZ D, GERARD C et al.: In vivo induction of interleukin 10 by anti-CD3 monoclonal antibody or bacterial lipopolysaccharide: differential modulation by cyclosporin A. J. Exf. Med. (1993) 177:551-555.
116. DUREZ P, APPELBOOM T, PIRA C et al.: Antiinflammatory properties of mycophenolate mofetil in murine endotoxemia: inhibition of TNF-alpha and upregulation of IL-10 release. Int. J. Immunopharmacol. (1999) 21:581-587.
117. CORRAL LG, HASLETT PA, MULLER GW et al.: Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J. Immunol. (1999) 163:380-386.
118. SAWICKA E, ZUANY-AMORIM C, MANLIUS C et al.: Inhibition of Th1- and Th2-mediated airway inflammation by the sphingosine 1-phosphate receptor agonist FTY720. J. Immunol. (2003) 171:6206-6214.
119. XYSTRAKIS E, KUSUMAKAR S, BOSWELL S et al.: Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. J. Clin. Invest. (2006) 116(1):146-155. Evidence that vitamin D3 and IL-10 can restore the reactivity of T cells from glucocorticoid-resistant asthma patients for the induction of IL-10 synthesis.
120. PASARE C, MEDZHITOV R: Toll-like receptors: balancing host resistance with immune tolerance. Curr. Opin. Immunol. (2003) 15:677-682.
121. KRIEG AM: CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. (2002) 20:709-760.
122. AKIRA S, TAKEDA K: Toll-like receptor signalling. Nat. Rev. Immunol. (2004) 4:499-511.
123. TIGHE H, TAKABAYASHI K, SCHWARTZ D et al.: Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J. Allergy Clin. Immunol. (2000) 106:124-134.
124. TULIC MK, FISET PO, CHRISTODOULOPOULOS P et al.: Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J. Allergy Clin. Immunol. (2004) 113:235-241.
125. BELKAID Y, ROUSE BT: Natural regulatory T cells in infectious disease. Nat. Immunol. (2005) 6:353-360.
126. MCGUIRK P, MCCANN C, MILLS KH: Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J. Exf. Med. (2002) 195:221-231.
127. LAVELLE EC, MCGUIRK P, MILLS KH: Molecules of infectious agents as immunomodulatory drugs. Curr. Top. Med. Chem. (2004) 4:499-508.
128. DONG X, BACHMAN LA, KUMAR R, GRIFFIN MD: Generation of antigen-specific, interleukin-10-producing T-cells using dendritic cell stimulation and steroid hormone conditioning. Transpl. Immunol. (2003) 11:323-333.
129. KALLIOMAKI M, ISOLAURI E: Role of intestinal flora in the development of allergy. Curr. Opin. Allergy Clin. Immunol. (2003) 3:15-20.
130. KALLIOMAKI M, SALMINEN S, POUSSA T, ARVILOMMI H, ISOLAURI E: Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet (2003) 361:1869-1871.
131. ZHU D, KEPLEY CL, ZHANG K et al.: A chimeric human-cat fusion protein blocks cat-induced allergy. Nat. Med. (2005) 11:446-449.